GreyWolf Therapeutics is a biotechnology company focused on developing novel cancer immunotherapies. The company leverages its proprietary platform to target immunosuppressive cells in the tumor microenvironment, aiming to enhance the immune system's ability to fight cancer.

Grey Wolf Therapeutics

GreyWolf Therapeutics

Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology and founded by experienced industry professionals Tom McCarthy (Executive Chairman), former President and CEO of Spinifex Pharmaceuticals and Peter Joyce (CEO), formerly of Vertex Pharmaceuticals. 

Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. We are targeting a key protein in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology. 

Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target. The Grey Wolf team is made up of experts in immuno-oncology, antigen presentation and drug discovery.

For more information, visit the website or email enquiries@gwt.bio.

COM:GREYWOLFTHERAPEUTICS

GreyWolf Therapeutics

locale

market

industry

website

crunchbase

linkedin

founding date

investor of

Metrics